[go: up one dir, main page]

EA200100869A1 - Кристаллическая форма эплеренона - Google Patents

Кристаллическая форма эплеренона

Info

Publication number
EA200100869A1
EA200100869A1 EA200100869A EA200100869A EA200100869A1 EA 200100869 A1 EA200100869 A1 EA 200100869A1 EA 200100869 A EA200100869 A EA 200100869A EA 200100869 A EA200100869 A EA 200100869A EA 200100869 A1 EA200100869 A1 EA 200100869A1
Authority
EA
Eurasian Patent Office
Prior art keywords
eplerenone
developed
preparation
crystalline form
aldosterone
Prior art date
Application number
EA200100869A
Other languages
English (en)
Other versions
EA008449B1 (ru
Inventor
Кэтлин П. Бартон
Генри Т. Год
Скотт Гэнсер
Клэй Р. Литтл
Партха С. Мудипалли
Томас Б. Борчардт
Марлон В. Карлос
Субхаш Десай
Леонард Дж. Ферро
Марк А. Питц
Дэниел Р. Пилипоскас
Йуен-Лунг Л. Синг
Гленн Л. Стал
Джозеф Дж. Вечорек
Крис Й. Йан
Original Assignee
Фармация Корпорейшн
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Фармация Корпорейшн filed Critical Фармация Корпорейшн
Publication of EA200100869A1 publication Critical patent/EA200100869A1/ru
Publication of EA008449B1 publication Critical patent/EA008449B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J19/00—Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 by a lactone ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07J—STEROIDS
    • C07J71/00—Steroids in which the cyclopenta(a)hydrophenanthrene skeleton is condensed with a heterocyclic ring
    • C07J71/0005—Oxygen-containing hetero ring
    • C07J71/001—Oxiranes
    • C07J71/0015—Oxiranes at position 9(11)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/28—Antiandrogens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/34—Gestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Hospice & Palliative Care (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Developing Agents For Electrophotography (AREA)
  • Crystals, And After-Treatments Of Crystals (AREA)

Abstract

Разработана новая кристаллическая форма (форма L) лекарственного средства эплеренона, представляющего собой антагонист альдостеронового рецептора, имеющая относительно высокую физическую стабильность при нормальных температурах хранения и применения. Также разработана фармацевтическая композиция, включающая форму L эплеренона, необязательно сочетающуюся с одной или несколькими другими твердыми формами эплеренона, в общем количестве в единичной препаративной лекарственной форме от примерно 10 до примерно 1000 мг и дополнительно включающая один или несколько фармацевтически приемлемых эксципиентов. Разработаны способы получения формы L эплеренона и получения композиций, включающих форму L эплеренона. Также разработан способ профилактики и/или лечения альдостерон-опосредованного болезненного состояния или заболевания, включающий введение субъекту терапевтически эффективного количества эплеренона, где, по крайней мере, часть присутствующего эплеренона представляет собой форму L эплеренона.Отчет о международном поиске был опубликован 2001.11.22.
EA200100869A 1999-12-08 2000-12-04 Кристаллическая форма эплеренона EA008449B1 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US16955699P 1999-12-08 1999-12-08
US16980799P 1999-12-08 1999-12-08
US16970799P 1999-12-08 1999-12-08
US16963999P 1999-12-08 1999-12-08
US16960899P 1999-12-08 1999-12-08
US16968399P 1999-12-08 1999-12-08
PCT/US2000/030178 WO2001041535A2 (en) 1999-12-08 2000-12-04 Eplerenone crystalline form

Publications (2)

Publication Number Publication Date
EA200100869A1 true EA200100869A1 (ru) 2002-04-25
EA008449B1 EA008449B1 (ru) 2007-06-29

Family

ID=27558586

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200100869A EA008449B1 (ru) 1999-12-08 2000-12-04 Кристаллическая форма эплеренона

Country Status (18)

Country Link
US (1) US20090149431A1 (ru)
EP (1) EP1175434A2 (ru)
JP (2) JP4219105B2 (ru)
KR (1) KR100584104B1 (ru)
CN (1) CN100413881C (ru)
AR (1) AR074665A2 (ru)
AU (1) AU2041101A (ru)
BR (1) BR0008054A (ru)
CA (1) CA2362845A1 (ru)
CO (1) CO5280205A1 (ru)
EA (1) EA008449B1 (ru)
HU (1) HUP0201457A3 (ru)
IL (2) IL144757A0 (ru)
MY (1) MY143571A (ru)
NO (1) NO20013857L (ru)
NZ (1) NZ513962A (ru)
PE (1) PE20010918A1 (ru)
WO (1) WO2001041535A2 (ru)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20010821A1 (it) * 2001-04-17 2002-10-17 Gienne Pharma S P A Impiego di composti derivati dallo spirolattone per inibire l'azione pro-fibrigenetica delle cellule stellate epatiche e delle cellule musco
US7235655B2 (en) 2002-03-22 2007-06-26 Pharmacia & Upjohn Company Processes to prepare eplerenone
ES2641144T3 (es) 2010-05-10 2017-11-07 Inserm (Institut National De La Santé Et De La Recherche Medicale) Métodos y composiciones para el tratamiento de la acumulación de líquido en y/o bajo la retina
US9241944B2 (en) 2010-06-16 2016-01-26 Institut National De La Santé Et De La Recherche Médicale (Inserm) Methods and compositions for stimulating reepithelialisation during wound healing
CN104844681B (zh) * 2014-02-13 2016-06-01 合肥久诺医药科技有限公司 一种l晶型依普利酮的精制方法
JP6835836B2 (ja) 2015-10-13 2021-02-24 アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル 脈絡膜血管新生の処置のための方法及び医薬組成物
US20190262363A1 (en) 2016-07-26 2019-08-29 INSERM (Institut National de la Santé et de la Recherche Médicale Antagonist of mineralocorticoid receptor for the treatment of osteoarthritis
CN108059648A (zh) * 2017-12-30 2018-05-22 合肥久诺医药科技有限公司 一种依普利酮溶剂合物及其制备方法
CN113173968A (zh) * 2021-03-19 2021-07-27 江苏康思尔医药科技有限公司 一种依普利酮的纯化方法
WO2023031277A1 (en) 2021-08-31 2023-03-09 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for the treatment of ocular rosacea

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559332A (en) * 1983-04-13 1985-12-17 Ciba Geigy Corporation 20-Spiroxanes and analogues having an open ring E, processes for their manufacture, and pharmaceutical preparations thereof
US4826689A (en) * 1984-05-21 1989-05-02 University Of Rochester Method for making uniformly sized particles from water-insoluble organic compounds
FR2634376B1 (fr) * 1988-07-21 1992-04-17 Farmalyoc Nouvelle forme unitaire, solide et poreuse comprenant des microparticules et/ou des nanoparticules, ainsi que sa preparation
IT1227626B (it) * 1988-11-28 1991-04-23 Vectorpharma Int Farmaci supportati aventi velocita' di dissoluzione aumentata e procedimento per la loro preparazione
IT1243390B (it) * 1990-11-22 1994-06-10 Vectorpharma Int Composizioni farmaceutiche in forma di particelle atte al rilascio controllato di sostanze farmacologicamente attive e procedimento per la loro preparazione.
US5552160A (en) * 1991-01-25 1996-09-03 Nanosystems L.L.C. Surface modified NSAID nanoparticles
US5145684A (en) * 1991-01-25 1992-09-08 Sterling Drug Inc. Surface modified drug nanoparticles
AU660852B2 (en) * 1992-11-25 1995-07-06 Elan Pharma International Limited Method of grinding pharmaceutical substances
US5346702A (en) * 1992-12-04 1994-09-13 Sterling Winthrop Inc. Use of non-ionic cloud point modifiers to minimize nanoparticle aggregation during sterilization
US5298262A (en) * 1992-12-04 1994-03-29 Sterling Winthrop Inc. Use of ionic cloud point modifiers to prevent particle aggregation during sterilization
US5302401A (en) * 1992-12-09 1994-04-12 Sterling Winthrop Inc. Method to reduce particle size growth during lyophilization
US5340564A (en) * 1992-12-10 1994-08-23 Sterling Winthrop Inc. Formulations comprising olin 10-G to prevent particle aggregation and increase stability
US5336507A (en) * 1992-12-11 1994-08-09 Sterling Winthrop Inc. Use of charged phospholipids to reduce nanoparticle aggregation
US5429824A (en) * 1992-12-15 1995-07-04 Eastman Kodak Company Use of tyloxapole as a nanoparticle stabilizer and dispersant
US5352459A (en) * 1992-12-16 1994-10-04 Sterling Winthrop Inc. Use of purified surface modifiers to prevent particle aggregation during sterilization
US5587143A (en) * 1994-06-28 1996-12-24 Nanosystems L.L.C. Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5585108A (en) * 1994-12-30 1996-12-17 Nanosystems L.L.C. Formulations of oral gastrointestinal therapeutic agents in combination with pharmaceutically acceptable clays
US5662883A (en) * 1995-01-10 1997-09-02 Nanosystems L.L.C. Microprecipitation of micro-nanoparticulate pharmaceutical agents
US5665331A (en) * 1995-01-10 1997-09-09 Nanosystems L.L.C. Co-microprecipitation of nanoparticulate pharmaceutical agents with crystal growth modifiers
US5560932A (en) * 1995-01-10 1996-10-01 Nano Systems L.L.C. Microprecipitation of nanoparticulate pharmaceutical agents
US5569448A (en) * 1995-01-24 1996-10-29 Nano Systems L.L.C. Sulfated nonionic block copolymer surfactants as stabilizer coatings for nanoparticle compositions
US5571536A (en) * 1995-02-06 1996-11-05 Nano Systems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5560931A (en) * 1995-02-14 1996-10-01 Nawosystems L.L.C. Formulations of compounds as nanoparticulate dispersions in digestible oils or fatty acids
US5503723A (en) * 1995-02-08 1996-04-02 Eastman Kodak Company Isolation of ultra small particles
US5534270A (en) * 1995-02-09 1996-07-09 Nanosystems Llc Method of preparing stable drug nanoparticles
US5518738A (en) * 1995-02-09 1996-05-21 Nanosystem L.L.C. Nanoparticulate nsaid compositions
US5622938A (en) * 1995-02-09 1997-04-22 Nano Systems L.L.C. Sugar base surfactant for nanocrystals
US5591456A (en) * 1995-02-10 1997-01-07 Nanosystems L.L.C. Milled naproxen with hydroxypropyl cellulose as a dispersion stabilizer
US5573783A (en) * 1995-02-13 1996-11-12 Nano Systems L.L.C. Redispersible nanoparticulate film matrices with protective overcoats
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US5580579A (en) * 1995-02-15 1996-12-03 Nano Systems L.L.C. Site-specific adhesion within the GI tract using nanoparticles stabilized by high molecular weight, linear poly (ethylene oxide) polymers
US5747001A (en) * 1995-02-24 1998-05-05 Nanosystems, L.L.C. Aerosols containing beclomethazone nanoparticle dispersions
US5565188A (en) * 1995-02-24 1996-10-15 Nanosystems L.L.C. Polyalkylene block copolymers as surface modifiers for nanoparticles
US5718919A (en) * 1995-02-24 1998-02-17 Nanosystems L.L.C. Nanoparticles containing the R(-)enantiomer of ibuprofen
PT973791E (pt) * 1995-12-11 2007-09-26 Searle Llc Processo para a preparação de um composto epoxi
ATE225367T1 (de) * 1996-12-11 2002-10-15 Searle & Co Verfahren zur herstellung von 3-keto-7alpha- alkoxycarbonyl- delta4,5-steroiden sowie zwischenprodukte
CA2364169A1 (en) * 1999-03-05 2000-09-08 G.D. Searle Llc Combination therapy of angiotensin converting enzyme inhibitor and epoxy-steroidal aldosterone antagonist for treatment of cardiovascular disease

Also Published As

Publication number Publication date
NO20013857D0 (no) 2001-08-08
JP2003515611A (ja) 2003-05-07
MY143571A (en) 2011-05-31
WO2001041535A3 (en) 2001-11-22
AU2041101A (en) 2001-06-18
EP1175434A2 (en) 2002-01-30
HUP0201457A2 (en) 2002-08-28
WO2001041535A2 (en) 2001-06-14
NO20013857L (no) 2001-10-08
KR20020003192A (ko) 2002-01-10
CA2362845A1 (en) 2001-06-14
NZ513962A (en) 2004-08-27
US20090149431A1 (en) 2009-06-11
BR0008054A (pt) 2002-03-12
JP2007016043A (ja) 2007-01-25
WO2001041535A9 (en) 2002-07-04
IL144757A (en) 2007-07-24
IL144757A0 (en) 2002-06-30
CN100413881C (zh) 2008-08-27
EA008449B1 (ru) 2007-06-29
CN1433427A (zh) 2003-07-30
HK1057220A1 (zh) 2004-03-19
AR074665A2 (es) 2011-02-02
CO5280205A1 (es) 2003-05-30
PE20010918A1 (es) 2001-09-10
JP4219105B2 (ja) 2009-02-04
KR100584104B1 (ko) 2006-05-30
HUP0201457A3 (en) 2003-07-28

Similar Documents

Publication Publication Date Title
EP0741567B1 (en) Inhibition of smooth muscle migration and proliferation with hydroxy carbazole compounds
WO2001087284A3 (en) Aldosterone antagonist composition for release during aldosterone acrophase
RU2002121507A (ru) Композиция фульвестранта
KR100322042B1 (ko) 비쇼그렌증후군성구강건조증치료제
CO5251419A1 (es) Composiciones nanoparticuladas de eplerenona
WO2001085257A3 (en) Opioid antagonist compositions and dosage forms
RU2010107843A (ru) Бупропиона гидробромид и его терапевтические применения
JP2007508336A5 (ru)
EA200100869A1 (ru) Кристаллическая форма эплеренона
RU2003100507A (ru) Фармацевтические композиции
JP2006515299A5 (ru)
RU2005122403A (ru) Композиции нестероидных противовоспалительных лекарственных средств, противозастойных средств и антигистаминов
EA200100871A1 (ru) Кристаллическая форма эплеренона, обладающая повышенной скоростью растворения
Weiner et al. Efficacy and safety of sustained-release diltiazem in stable angina pectoris
JP2004529207A (ja) Ｌｈｒｈアンタゴニストの中間の用量での痴呆及び神経変性疾患の治療
JPH10158169A (ja) 塩化トロスピウムを含んだ医薬製剤、その調整方法および使用方法
Gaudilliere et al. To market, to market—2000
JP4542777B2 (ja) 肺高血圧症を予防または治療するのに用いられる医薬の製造のためのイルベサルタンの使用
JP2005187328A (ja) イブプロフェン含有解熱鎮痛組成物、及び感冒薬
US20220401423A1 (en) Methods for treating inflammatory bowel disease
KR950701344A (ko) 엔도텔린 길항제 Ⅱ(Endothelin Antagonists Ⅱ)
Winniford et al. Calcium antagonists in patients with cardiovascular disease: Current perspectives
JPS5942316A (ja) 睡眠障害治療剤
RU2003104798A (ru) Содержащие циланзетрон лекарственные средства для лечения не страдающих запорами пациентов мужского пола с синдромом раздраженного кишечника (срк)
BR0113140A (pt) Antagonistas de receptor de ccr1 não peptìdico em combinação com ciclosporina a para o tratamento da rejeição de transplante de coração

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ BY KZ KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): RU